Home/Filings/8-K/0001104659-26-009747
8-K//Current report

Gain Therapeutics, Inc. 8-K

Accession 0001104659-26-009747

$GANXCIK 0001819411operating

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 4:25 PM ET

Size

4.2 MB

Accession

0001104659-26-009747

Research Summary

AI-generated summary of this filing

Updated

Gain Therapeutics Files Regulation FD Disclosure, Posts Investor Presentation

What Happened
Gain Therapeutics, Inc. (GANX) filed a Current Report on Form 8-K on February 3, 2026 under Item 7.01 (Regulation FD Disclosure) to announce that it posted slides describing its business on its website. The slides were included in the filing as Exhibit 99.1. The 8-K also lists exhibit attachments (including the Inline XBRL cover page, Exhibit 104).

Key Details

  • Filing date: February 3, 2026 (Form 8-K).
  • Item reported: 7.01 — Regulation FD Disclosure; slides attached as Exhibit 99.1.
  • Exhibit listing: Exhibit 99.1 (Investor Presentation) and Exhibit 104 (Cover Page Interactive Data File).
  • The filing does not report earnings, financial results, executive changes, mergers, or other material corporate events.

Why It Matters
This filing publicly shares Gain Therapeutics’ investor presentation under Regulation FD, meaning the company disclosed these slides broadly rather than selectively. For investors, this is informational material about the company’s business and should not be interpreted as a quarterly earnings release or a change in management. Review the posted presentation (available on the company website and in the SEC filing) for details; monitor future SEC filings for material financial results or other significant events.

Issuer

Gain Therapeutics, Inc.

CIK 0001819411

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001819411

Filing Metadata

Form type
8-K
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:25 PM ET
Size
4.2 MB